CJC-1295 vs SLU-PP-332
Side-by-Side Comparison
| Attribute | Cjc 1295 | Slu Pp 332 |
|---|---|---|
| Category | Growth Hormone Secretagogue | Experimental Exercise Mimetic |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous... | SLU-PP-332 binds and activates all three estrogen-related receptors (ERRs), which are orphan nuclear receptors that serve as master transcriptional regulators of energy metabolism. |
| Evidence Rating | D — Preclinical | D — Animal/Preclinical Only |
| Clinical Status | Research-only / Not approved for human use | Preclinical only. Published murine studies from Washington University. No human trials planned or initiated. |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | CRITICAL: No human safety data exists; All safety information derived from mouse studies only |
| Route | Subcutaneous | Subcutaneous injection (EXPERIMENTAL — extrapolated from murine oral dosing) |
| Dose Range | No DAC: 100 mcg before bed daily; DAC: 1–2 mg 2–3x weekly | 1250-2500 mcg daily (SPECULATIVE — NO HUMAN DATA) |
| Frequency | Once daily (no DAC) or 2–3 times weekly (with DAC) | Twice daily |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | N/A |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | Unknown in humans (short in mice, necessitating twice-daily dosing) |
Overview
CJC-1295 and SLU-PP-332 are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
SLU-PP-332 — Mechanism & Evidence
SLU-PP-332 is a small-molecule pan-agonist of estrogen-related receptors (ERRalpha, ERRbeta, ERRgamma) developed at Washington University in St. Louis. It activates the aerobic exercise gene program, increasing oxidative muscle fiber content, mitochondrial respiration, and exercise capacity in mice without training. It represents a fundamentally different approach from AICAR (AMPK activation) by targeting the transcriptional master regulators of oxidative metabolism. CRITICAL: No human trials exist; all data is from murine studies only.
Key claims: Increases exercise endurance without training; Shifts muscle fiber type toward oxidative phenotype; Protects against muscular dystrophy in mice.
Shared Research Applications
Both peptides are studied for: Body Composition.
CJC-1295 is also researched for: Anti-Aging.
SLU-PP-332 is also researched for: Metabolic Health.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
SLU-PP-332: CRITICAL: No human safety data exists All safety information derived from mouse studies only Mice tolerated twice-daily dosing without reported toxicity
Related Products
Related Research News
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.
CJC-1295 + Ipamorelin: Growth Hormone Stack Mechanics
CJC-1295 and Ipamorelin form the most studied growth hormone peptide combination in research. They target separate receptor pathways to boost GH secretion through the somatotropic axis. This stack produces amplified GH pulses, with preclinical data showing 3 to 5 times baseline levels versus 1.5 to 2 times alone.
Ipamorelin: Selective GH Secretagogue for Clean Pulsatile Release
Ipamorelin, a third-generation GHS-R1a agonist (CAS 170851-70-4), stimulates pulsatile growth hormone release without elevating cortisol or prolactin, unlike earlier GHRPs. This selectivity supports precise research into GH axis effects, IGF-1 pathways, body composition, recovery, and sleep. Studies highlight its role in anabolic processes and synergy with CJC-1295 for enhanced GH output.